1-3 of 3
Alexander Perl
Close
Sort by
Journal Articles

A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia

Clinical Trials & Observations
Mark Levis, Alexander Perl, Gary Schiller, Amir T. Fathi, Gail Roboz, Eunice S. Wang, Jessica Altman, Trivikram Rajkhowa, Makoto Ando, Takeaki Suzuki, Ruth Ann Subach, Gary Maier, Timothy Madden, Mary Johansen, Kin Cheung, Michael Kurman, Catherine Smith
Journal: Blood Advances
Blood Adv (2024) 8 (10): 2527–2535.
https://doi.org/10.1182/bloodadvances.2023010619
Published: 2024
Includes: Supplemental data
Journal Articles

Vitamin C deficiency in patients with acute myeloid leukemia: a case series and review of the literature

Heather C. Milbar, Avrom Caplan, Robert D. Schwab, Alexandra J. Coromilas, Emily Baumrin, Amy Forrestel, Katharine T. Steele, Robert G. Micheletti, Alexander Perl, Misha Rosenbach
Journal: Blood Advances
Blood Adv (2023) 7 (19): 5780–5783.
https://doi.org/10.1182/bloodadvances.2023009923
Published: 2023
Journal Articles

Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinib

Clinical Trials & Observations
Cheryl A. C. Peretz, Lisa H. F. McGary, Tanya Kumar, Hunter Jackson, Jose Jacob, Robert Durruthy-Durruthy, Mark J. Levis, Alexander Perl, Benjamin J. Huang, Catherine C. Smith
Journal: Blood Advances
Blood Adv (2021) 5 (5): 1437–1441.
https://doi.org/10.1182/bloodadvances.2020003398
Published: 2021
Includes: Supplemental data